WallStreetZenWallStreetZen

NASDAQ: ASLN
Aslan Pharmaceuticals Ltd Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for ASLN

Based on 2 analysts offering 12 month price targets for Aslan Pharmaceuticals Ltd.
Min Forecast
$4.00+545.16%
Avg Forecast
$5.50+787.1%
Max Forecast
$7.00+1,029.03%

Should I buy or sell ASLN stock?

Based on 2 analysts offering ratings for Aslan Pharmaceuticals Ltd.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ASLN stock forecasts and price targets.

ASLN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Piper Sandler
Top 11%
90
Strong BuyMaintains$4.00+545.16%2022-09-16Find out why
HC Wainwright & Co.
Top 5%
96
BuyMaintains$7.00+1,029.03%2022-08-15

1 of 1

Forecast return on equity

Is ASLN forecast to generate an efficient return?
Company
-864.64%
Industry
18.78%
Market
118.57%
ASLN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ASLN forecast to generate an efficient return on assets?
Company
-350.39%
Industry
14.1%
ASLN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ASLN earnings per share forecast

What is ASLN's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.65
Avg 2 year Forecast
-$0.88
Avg 3 year Forecast
-$0.58

ASLN revenue forecast

What is ASLN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$14.5M
Avg 2 year Forecast
$90.8M
Avg 3 year Forecast
$212.3M

ASLN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ASLN$0.62$5.50+787.10%Strong Buy
BTTX$1.82$17.00+834.07%Strong Buy
SLS$2.10$6.00+185.71%Strong Buy
AMTI$1.12$35.50+3,069.64%Buy
RUBY$0.48$3.50+624.64%Hold

Aslan Pharmaceuticals Stock Forecast FAQ

Is Aslan Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ASLN) stock is to Strong Buy ASLN stock.

Out of 2 analysts, 1 (50%) are recommending ASLN as a Strong Buy, 1 (50%) are recommending ASLN as a Buy, 0 (0%) are recommending ASLN as a Hold, 0 (0%) are recommending ASLN as a Sell, and 0 (0%) are recommending ASLN as a Strong Sell.

If you're new to stock investing, here's how to buy Aslan Pharmaceuticals stock.

What is ASLN's earnings growth forecast for 2022-2024?

(NASDAQ: ASLN) Aslan Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Aslan Pharmaceuticals's earnings in 2022 is -$43,664,424.On average, 3 Wall Street analysts forecast ASLN's earnings for 2022 to be -$226,670,187, with the lowest ASLN earnings forecast at -$275,491,458, and the highest ASLN earnings forecast at -$146,463,813. On average, 3 Wall Street analysts forecast ASLN's earnings for 2023 to be -$306,876,561, with the lowest ASLN earnings forecast at -$481,238,244, and the highest ASLN earnings forecast at -$174,361,683.

In 2024, ASLN is forecast to generate -$202,259,552 in earnings, with the lowest earnings forecast at -$202,259,552 and the highest earnings forecast at -$202,259,552.

What is ASLN's revenue growth forecast for 2025-2027?

(NASDAQ: ASLN) Aslan Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Aslan Pharmaceuticals's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast ASLN's revenue for 2025 to be $5,056,488,793, with the lowest ASLN revenue forecast at $5,056,488,793, and the highest ASLN revenue forecast at $5,056,488,793. On average, 1 Wall Street analysts forecast ASLN's revenue for 2026 to be $31,657,107,075, with the lowest ASLN revenue forecast at $31,657,107,075, and the highest ASLN revenue forecast at $31,657,107,075.

In 2027, ASLN is forecast to generate $74,023,508,689 in revenue, with the lowest revenue forecast at $74,023,508,689 and the highest revenue forecast at $74,023,508,689.

What is ASLN's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: ASLN) forecast ROA is -350.39%, which is lower than the forecast US Biotechnology industry average of 14.1%.

What is ASLN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ASLN price target, the average ASLN price target is $5.50, with the highest ASLN stock price forecast at $7.00 and the lowest ASLN stock price forecast at $4.00.

On average, Wall Street analysts predict that Aslan Pharmaceuticals's share price could reach $5.50 by Sep 16, 2023. The average Aslan Pharmaceuticals stock price prediction forecasts a potential upside of 787.1% from the current ASLN share price of $0.62.

What is ASLN's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: ASLN) Aslan Pharmaceuticals's current Earnings Per Share (EPS) is -$0.60. On average, analysts forecast that ASLN's EPS will be -$0.65 for 2022, with the lowest EPS forecast at -$0.79, and the highest EPS forecast at -$0.42. On average, analysts forecast that ASLN's EPS will be -$0.88 for 2023, with the lowest EPS forecast at -$1.38, and the highest EPS forecast at -$0.50. In 2024, ASLN's EPS is forecast to hit -$0.58 (min: -$0.58, max: -$0.58).

What is ASLN's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: ASLN) forecast ROE is -864.64%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.